Abstract: There are provided a compound of Formula (1) and a labeled biological substance having the compound. A ring Z1 and a ring Z2 represent a 6-membered ring formed of a ring-constituting atom selected from a carbon atom and a nitrogen atom. R1 to R4, R11 to R13, L1, and L2 represents specific groups, and n, ?1, and ?2 represent specific numbers. At least one of R11, R12, or R13 contains a carboxy group or a substituent capable of being bonded to a biological substance. the compound represented by Formula (1) has at least one structure represented by —(CH2—CH2—O)m—R21, where R21 represents a specific group, and m represents a specific number. The compound represented by Formula (1) is a neutral compound.

Abstract: The present invention is to provide a photoelectric conversion element with an excellent photoelectric conversion efficiency, an imaging element, an optical sensor, and a compound. The photoelectric conversion element of the present invention includes, in the following order, a conductive film, a photoelectric conversion film, and a transparent conductive film, in which the photoelectric conversion film contains a compound represented by Formula (1).

Abstract: There are provided a fluorescent compound of the following formula or a salt thereof and a labeled biological substance. Y represents —NR10R11 or —OR12, and R1 to R12, R21 to R23, and Z represent specific groups and satisfy the following regulations. At least one of R21 or R22 is an alkenyl group, an alkynyl group, an aryl group, or a heteroaryl group. In a case of R21=an aryl group and R22=an alkyl group or an aryl group, at least R7 and R8, or R10 and R11 are bonded to each other to form a 4-membered ring. A compound of Formula (I) or (II) or a salt thereof satisfies condition ?, and a compound of Formula (III) or (IV) or a salt thereof satisfies condition ?. (Condition ?) In a case where Z is an aryl group, the aryl group has a specific structure. (Condition ?) At least R7 and R8, or R10 and R11 are bonded to each other to form a 4-membered ring.

Abstract: Provided are the following compound and a fluorescently labeled biological substance having this fluorescent compound. X represents CR7 or N. R1 to R7, Q1, and Q2 represent a hydrogen atom, a halogen atom, a cyano group, or a group represented by Formula (A), and adjacent substituents may form a ring structure. However, at least one of R3, R4, R7, Q1, or Q2 contains, as a hydrophilic group, at least one of a carboxy group or a salt thereof, a sulfo group or a salt thereof, a phosphono group or a salt thereof, an onio group, or a polyamino acid residue, where at least one of Q1 or Q2 represents an alkyl group.

Abstract: Provided are any one of the following fluorescent compounds and a fluorescent labeled biological substance having this fluorescent compound. X represents CR5 or N, and R1 to R7, Q1, Q2, L1, and L2 each represent a specific group. a ring ?1 and a ring ?2 are a 5- to 8-membered ring, At least one of R1 to R7, L1, L2, Q1, or Q2 has a specific hydrophilic group. However, in a case where the ring ?1 and the ring ?2 are a 6-membered ring, and L1 and L2 are an arylene group, R5 is not an aryl group substituted with a linear alkyl group having 18 or more carbon atoms. In addition to the regulation of the ring ?1, the ring ?2, L1, and L2, in a case where R5 has a substituent having a dipyrromethene boron complex structure, the dipyrromethene boron complex structure has a structure in which a dipyrromethene skeleton is coordinately bonded to a boron atom in the tridentate or tetradentate coordination.

Abstract: There is provided a morpholine derivative represented by General Formula [1A] or a salt thereof (In the formula, a ring A represents a ring represented by General Formula [I]; * represents a bonding position; Z2 represents CH or the like; Z1 represents CR6 or the like; R6 represents a hydrogen atom or the like; X1 represents CHR7 or the like; R7 represents a hydrogen atom or the like; X2 represents CH2 or the like; R1 and R2 are the same as or different from each other, and each of R1 and R2 represents a hydrogen atom or the like; R3, R4, and R5 are the same as or different from each other, and each of R3, R4, and R5 represents a hydrogen atom, NRaRb, or the like; and each of Ra and Rb represents a hydrogen atom, a C1-8 alkyl group which may have a substituent, or the like).

Abstract: There is provided a morpholine derivative represented by General Formula [1A] or a salt thereof. (In the formula, a ring A represents a ring represented by General Formula [I]; * represents a bonding position; Z2 represents CH or the like; Z1 represents CR6 or the like; R6 represents a hydrogen atom or the like; X1 represents CHR7 or the like; R7 represents a hydrogen atom or the like; X2 represents CH2 or the like; R1 and R2 are the same as or different from each other, and each of R1 and R2 represents a hydrogen atom or the like; R3, R4, and R5 are the same as or different from each other, and each of R3, R4, and R5 represents a hydrogen atom, NRaRb, or the like; and each of Ra and Rb represents a hydrogen atom, a C1-8 alkyl group which may have a substituent, or the like.

Abstract: A compound represented by following formula (I): A-L-{D1-(E)q-D2-(B)m—Z1—R}p. In the formula, A represents a p-valent chain or cyclic residue; L represents a single bond or a divalent linking group; p represents an integer of 2 or more; D1 represents a carbonyl group (—C(?O)—) or a sulfonyl group (—S(?O)2—); D2 represents a carbonyl group (—C(?O)—), a sulfonyl group (—S(?O)2—), a carboxyl group (—C(?O)O—), a sulfonyloxyl group (—S(?O)2O—), a carbamoyl group (—C(?O)N(Alk)-) or a sulfamoyl group (—S(?O)2N(Alk)-); E represents a divalent group; and R represents a hydrogen atom, a substituted or non-substituted C8 or longer alkyl group, a perfluoroalkyl group or a trialkylsilyl group.

Abstract: [Problem] Provided is a novel lubricant composition that is useful as a material of a lubricating layer of a magnetic recording medium. [Means for Resolution] The lubricant composition contains at least one kind of compound represented by the following Formula (1). In the formula, X represents a cyclic group that may be substituted, and Y represents a single bond or a linking group having a valency of 2 or more. Here, at least one of X and Y includes 1 or more polar groups such as a hydroxyl group; Z represents a linking group having a valency of 2 or more and constituted with a carbon atom (C), a fluorine atom (F), and 1 or 2 kinds of arbitrary atoms (here, a hydrogen atom is excluded); n represents a real number of 1 to 10; m represents a real number of 0 to 1; and s and t independently represent a real number of 1 or greater.

Abstract: The object of the present invention is to provide a compound and a pharmaceutical composition having excellent Syk inhibitory activity. According to the present invention, a nicotinamide derivative represented by the following formula (I) or a salt thereof is provided, wherein R1 is a substituent represented by the following formula (II-1), (III-1), or (IV-1) (wherein R3, R4, R5, n, and X1 have the same definitions as those described in the specification), and R2 is a pyridyl, indazolyl, phenyl, pyrazolopyridyl, benzisoxazolyl, pyrimidinyl, or quinolyl group, each of which optionally has at least one substituent.

Abstract: An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl group, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R4 and R5 each independently represent a hydrogen atom; and R2 and R4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

Abstract: The object of the present invention is to provide a compound and a pharmaceutical composition having excellent Syk inhibitory activity. According to the present invention, a nicotinamide derivative represented by the following formula (I) or a salt thereof is provided, wherein R1 is a substituent represented by the following formula (II-1), (III-1), or (IV-1) (wherein R3, R4, R5, n, and X1 have the same definitions as those described in the specification), and R2 is a pyridyl, indazolyl, phenyl, pyrazolopyridyl, benzisoxazolyl, pyrimidinyl, or quinolyl group, each of which optionally has at least one substituent.

Abstract: An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl group, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R4 and R5 each independently represent a hydrogen atom; and R2 and R4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

Abstract: An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl group, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R4 and R5 each independently represent a hydrogen atom; and R2 and R4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

Abstract: A compound represented by following formula (I): A-L-{D1-(E)q-D2-(B)m—Z1—R}p. In the formula, A represents a p-valent chain or cyclic residue; L represents a single bond or a divalent linking group; p represents an integer of 2 or more; D1 represents a carbonyl group (—C(?O)—) or a sulfonyl group (—S(?O)2—); D2 represents a carbonyl group (—C(?O)—), a sulfonyl group (—S(?O)2—), a carboxyl group (—C(?O)O—), a sulfonyloxyl group (—S(?O)2O—), a carbamoyl group (—C(?O)N(Alk)-) or a sulfamoyl group (—S(?O)2N(Alk)-); E represents a divalent group; and R represents a hydrogen atom, a substituted or non-substituted C8 or longer alkyl group, a perfluoroalkyl group or a trialkylsilyl group.

Abstract: To provide a novel compound. It is disclosed a compound represented by following formula (I): A-L-{D1-(E)q-D2-(B)m—Z1—R}p. In the formula, A represents a p-valent chain or cyclic residue; L represents a single bond or a divalent linking group; p represents an integer of 2 or more; D1 represents a carbonyl group (—C(?O)—) or a sulfonyl group (—S(?O)2—); D2 represents a carbonyl group (—C(?O)—), a sulfonyl group (—S(?O)2—), a carboxyl group (—C(?O)O—), a sulfonyloxyl group (—S(?O)2O—), a carbamoyl group (—C(?O)N(Alk)-) or a sulfamoyl group (—S(?O)2N(Alk)-); E represents a divaltn group; and R represents a hydrogen atom, a substituted or non-substituted C8 or longer alkyl group, a perfluoroalkyl group or a trialkylsilyl group.

Abstract: An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl group, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R4 and R5 each independently represent a hydrogen atom; and R2 and R4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

Abstract: [Problem] Provided is a novel lubricant composition that is useful as a material of a lubricating layer of a magnetic recording medium. [Means for Resolution] The lubricant composition contains at least one kind of compound represented by the following Formula (1). In the formula, X represents a cyclic group that may be substituted, and Y represents a single bond or a linking group having a valency of 2 or more. Here, at least one of X and Y includes 1 or more polar groups such as a hydroxyl group; Z represents a linking group having a valency of 2 or more and constituted with a carbon atom (C), a fluorine atom (F), and 1 or 2 kinds of arbitrary atoms (here, a hydrogen atom is excluded); n represents a real number of 1 to 10; m represents a real number of 0 to 1; and s and t independently represent a real number of 1 or greater.

Abstract: To provide a novel compound. It is disclosed a compound represented by following formula (I): A-L-{D1-(E)q-D2-(B)m—Z1—R}p. In the formula, A represents a p-valent chain or cyclic residue; L represents a single bond or a divalent linking group; p represents an integer of 2 or more; D1 represents a carbonyl group (—C(?O)—) or a sulfonyl group (—S(?O)2—); D2 represents a carbonyl group (—C(?O)—), a sulfonyl group (—S(?O)2—), a carboxyl group (—C(?O)O—), a sulfonyloxyl group (—S(?O)2O—), a carbamoyl group (—C(?O)N(Alk)-) or a sulfamoyl group (—S(?O)2N(Alk)-); E represents a divaltn group; and R represents a hydrogen atom, a substituted or non-substituted C8 or longer alkyl group, a perfluoroalkyl group or a trialkylsilyl group.

Abstract: A hydrophilic film forming composition which is used for forming on the surface of a support of every sort a hydrophilic film provided with anti-fogging properties, abrasion resistance and antibacterial properties and having more favorable antifouling properties is provided. A hydrophilic member having an excellent anti-fogging, abrasion-resistant, antibacterial and antifouling surface provided with a hydrophilic film formed of the instant hydrophilic film forming composition on the surface of an appropriate support is provided. A hydrophilic film forming composition including (A) a positively charged nitrogen atom-containing compound having a Log P of not more than 2; (B) a hydrolyzable silyl group-containing hydrophilic polymer; and (C) a metal complex catalyst. A hydrophilic member including a support having the instant hydrophilic film forming composition coated thereon.